How do you decide on hormone replacement therapy in women with risk of venous thromboembolism?

Kuh, 1997, Women's health in midlife: the influence of the menopause, social factors and health in earlier life, Br J Obstet Gynaecol, 104, 923, 10.1111/j.1471-0528.1997.tb14352.x Cosman, 2014, Clinician's guide to prevention and treatment of osteoporosis, Osteoporos Int, 25, 2359, 10.1007/s00198-014-2794-2 Sassarini, 2015, Oestrogen replacement in postmenopausal women, Age Ageing, 44, 551, 10.1093/ageing/afv069 Heit, 2016, The epidemiology of venous thromboembolisam, J Thromb Thrombolysis, 41, 3, 10.1007/s11239-015-1311-6 Sweetland, 2012, Million women study collaborators. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study, J Thromb Haemost, 10, 2277, 10.1111/j.1538-7836.2012.04919.x Ohira, 2010, Reproductive history, hormone replacement, and incidence of venous thromboembolism: the longitudinal investigation of thromboembolism etiology, Br J Haematol, 149, 606, 10.1111/j.1365-2141.2010.08128.x Roach, 2013, The risk of venous thrombosis in women over 50years old using oral contraception or postmenopausal hormone therapy, J Thromb Haemost, 11, 124, 10.1111/jth.12060 Lowe, 2000, Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45–64years. Relationships to hormone replacement therapy, Thromb Haemost, 83, 530, 10.1055/s-0037-1613857 Høibraaten, 2001, Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial, Br J Haematol, 115, 415, 10.1046/j.1365-2141.2001.03111.x Post, 2003, Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women, Arterioscler Thromb Vasc Biol, 23, 1116, 10.1161/01.ATV.0000074146.36646.C8 Tchaikovski, 2010, Mechanisms of estrogen-induced venous thromboembolism, Thromb Res, 126, 5, 10.1016/j.thromres.2010.01.045 Bajzar, 1996, An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V Leiden, J Biol Chem, 271, 22949, 10.1074/jbc.271.38.22949 Parker, 2004, Leiden inhibits fibrinolysis in vivo, Circulation, 110, 3594, 10.1161/01.CIR.0000148781.87906.C0 van Baal, 2000, Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study, Thromb Haemost, 83, 29, 10.1055/s-0037-1613752 Douketis, 2003, The effect of prothrombotic blood abnormalities on the association between hormone replacement therapy and venous thromboembolism, J Thromb Haemost, 1 Rabbani, 2002, Oral conjugated equine estrogen increases plasma von Willebrand factor in postmenopausal women, J Am Coll Cardiol, 40, 1991, 10.1016/S0735-1097(02)02565-2 van Baal, 1999, Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women, Fertil Steril, 71, 663, 10.1016/S0015-0282(98)00513-5 Cushman, 1999, Effect of postmenopausal hormones on inflammation-sensitive proteins: the postmenopausal estrogen/progestin interventions (PEPI) study, Circulation, 100, 717, 10.1161/01.CIR.100.7.717 Blondon, 2014, Differential associations of oral estradiol and conjugated equine estrogen with hemostatic biomarkers, J Thromb Haemost, 12, 879, 10.1111/jth.12560 Douketis, 2000, The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of the literature, Thromb Res, 99, 25, 10.1016/S0049-3848(00)00217-6 Canonico, 2008, Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis, BMJ, 336, 1227, 10.1136/bmj.39555.441944.BE Douketis, 2005, Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study, J Thromb Haemost, 3, 943, 10.1111/j.1538-7836.2005.01268.x Grady, 2000, Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The heart and estrogen/progestin replacement study, Ann Intern Med, 132, 689, 10.7326/0003-4819-132-9-200005020-00002 Perez, 1997, Hormone replacement therapy and risk of venous thromboembolism: population based case–control study, BMJ, 314, 796, 10.1136/bmj.314.7083.796 Smith, 2004, Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis, JAMA, 292, 1581, 10.1001/jama.292.13.1581 Daly, 1996, Case–control study of venous thromboembolism risk in users of hormone replacement therapy, Lancet, 348, 1027, 10.1016/S0140-6736(96)24041-3 Grodstein, 1996, Prospective study of exogenous hormones and risk of pulmonary embolism in women, Lancet, 348, 983, 10.1016/S0140-6736(96)07308-4 Renoux, 2010, Hormone replacement therapy and the risk of venous thromboembolism: a population-based study, J Thromb Haemost, 8, 979, 10.1111/j.1538-7836.2010.03839.x Files, 2011, Bioidentical hormone therapy, Mayo Clin Proc, 86, 673, 10.4065/mcp.2010.0714 Pérez Gutthann, 1997, Hormone replacement therapy and risk of venous thromboembolism: population based case-control study, BMJ, 314, 796, 10.1136/bmj.314.7083.796 Canonico, 2010, Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study, Arterioscler Thromb Vasc Biol, 30, 340, 10.1161/ATVBAHA.109.196022 Olié, 2011, Postmenopausal hormone therapy and venous thromboembolism, Thromb Res, 127, S26, 10.1016/S0049-3848(11)70008-1 Straczek, 2005, Estrogen and thromboembolism risk (ESTHER) study group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration, Circulation, 112, 3495, 10.1161/CIRCULATIONAHA.105.565556 Canonico, 2007, Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study, Circulation, 115, 840, 10.1161/CIRCULATIONAHA.106.642280 Mohammed, 2015, Oral vs transdermal estrogen therapy and vascular events: a systematic review and meta-analysis, J Clin Endocrinol Metab, 100, 4012, 10.1210/jc.2015-2237 Olie, 2010, Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women, Curr Opin Hematol, 17, 457, 10.1097/MOH.0b013e32833c07bc Oger, 2003, For the SARAH investigators. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial, Arterioscler Thromb Vasc Biol, 23, 1671, 10.1161/01.ATV.0000087141.05044.1F Ballagh, 2005, Vaginal hormone therapy for urogenital and menopausal symptoms, Semin Reprod Med, 23, 26, 10.1055/s-2005-869480 Speroff, 2003, Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms, Obstet Gynecol, 102, 823 Henriksson, 1996, One-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging, Am J Obstet Gynecol, 174, 85, 10.1016/S0002-9378(96)70378-2 Rossouw, 2002, Writing group for the women's health initiative investigators. Risk and benefits of estrogen plus progestin in health postmenopausal women, JAMA, 288, 321, 10.1001/jama.288.3.321 Cushman, 2004, Women's health initiative investigators. Estrogen plus progestin and risk of venous thrombosis, JAMA, 292, 1573, 10.1001/jama.292.13.1573 Kristensen, 2006, Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish osteoporosis prevention study (DOPS), Thromb Haemost, 95, 915, 10.1160/TH05-12-0824 Canonico, 2006, Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormonetherapy by route of estrogen administration. The ESTHER study, J Thromb Haemos, 4, 1259, 10.1111/j.1538-7836.2006.01933.x Wu, 2005, Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The thrombosis: risk and economic assessment of thrombophilia screening (TREATS) study, Thromb Haemost, 94, 17, 10.1160/TH04-11-0759 Rosendaal, 2002, Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis, Br J Haematol, 116, 851, 10.1046/j.0007-1048.2002.03356.x Herrington, 2002, Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease, Arterioscler Thromb Vasc Biol, 22, 1012, 10.1161/01.ATV.0000018301.91721.94 Høibraaten, 2000, Increased risk of recurrent venous thromboembolism during hormone replacement therapy—results of the randomized, double-blind, placebo controlled estrogen in venous thromboembolism trial (EVTET), Thromb Haemost, 84, 961 Royal College of Obstetricians & Gynaecologists, 2011 Olie, 2011, Hormone therapy and recurrence of venous thromboembolism among postmenopausal women, Menopause, 18, 488, 10.1097/gme.0b013e3181f9f7c3 Stam-Slob, 2015, Contraceptive and hormonal treatment options for women with history of venous thromboembolism, BMJ, 352 Nedrow, 2006, Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review, Arch Intern Med, 166, 1453, 10.1001/archinte.166.14.1453 Pinkerton, 1999, Alternatives to the use of estrogen in postmenopausal women, Endocr Rev, 20, 308, 10.1210/edrv.20.3.0369 Royal College of Obstetricians & Gynaecologists Ellison, 2000, Drug points: apparent interaction between warfarin and levonorgestrel used for emergency contraception, BMJ, 321, 1382, 10.1136/bmj.321.7273.1382 McLintock, 2003, Interaction between hormone replacement therapy preparations and oral anticoagulant therapy, BJOG, 110, 777, 10.1111/j.1471-0528.2003.02035.x